Browsing Category
Pharma Industry News
4719 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Moleculin’s $9.3m raise adds 49.5m potential shares after MIRACLE update
Moleculin’s 37% MIRACLE remission signal is followed by a $9.3 million offering, heavy warrant dilution and a 59% stock drop.
Cytokinetics secures UK approval and NHS access for aficamten in obstructive HCM
UK approval and NICE reimbursement give aficamten access to 6,600 patients as Cytokinetics expands its global HCM commercial launch.
Novo Nordisk’s $2.1bn Corvidia bet faces impairment after ZEUS trial miss
Ziltivekimab’s Phase 3 failure sends Novo Nordisk down 9%, triggers a Corvidia impairment and weakens its cardiovascular expansion strategy.
AbbVie (ABBV) raises 2026 revenue guidance as Skyrizi and Rinvoq lift Q2 revenue to $17bn
AbbVie posted Q2 2026 revenue of $16.99 billion as Skyrizi crossed $5.5bn quarterly, but the pending $10.9bn Apogee deal trimmed 2026 adjusted EPS guidance.
Hopstem’s off-the-shelf neural cell therapy now targets three major brain injury markets
Two FDA clearances expand Hopstem’s hNPC01 into a three-indication neural cell platform spanning stroke and traumatic brain injury.
TScan launches Phase 3 ALLOHA-2 with $128m in cash and a looming funding gap
TSC-101 enters Phase 3 as TScan weighs promising donor-chimerism data against manufacturing complexity and a pre-readout funding gap.
Deramiocel’s 9 to 3 FDA panel defeat wipes out half of Capricor’s value before August decision
Capricor loses half its value after a 9 to 3 FDA vote puts deramiocel approval, an $80 million milestone and its launch strategy at risk.
Ocugen pairs OCU410 regulatory progress with a $130m balance-sheet reset
OCU410 gains FDA RMAT status as Ocugen prepares a 300-patient Phase 3 trial and funds development with convertible debt.
Novartis wins FDA nod for Pluvicto in hormone-sensitive prostate cancer, nearly doubling its addressable pool
FDA's mHSPC label nod nearly doubles Pluvicto's addressable pool. Novartis' five RLT plants and payer coverage now decide how fast $651M Q2 sales scale.
Dyne’s FORCE RNA therapy reversed muscle damage in mice, and its first FSHD trial is now cleared
DYNE-302 enters clinical development after FDA clearance as Dyne expands its FORCE pipeline following a $431.4 million equity raise.